Indoco Remedies' Goa Plant Clears UKMHRA cGMP Inspection
Mumbai: Indoco Remedies Limited announced that the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) inspected its solid dosage manufacturing facility in Goa (Plant I) from September 7 to September 9, 2026.
The UK-MHRA current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations.
Commenting on the development, Aditi Panandikar, Managing Director – Indoco Remedies Ltd. said, “This plant has been consistently catering to the regulated markets of UK, Europe, South Africa, New Zealand, Australia and Canada for several years and is expected to contribute to approx. 30% of total international business. The successful completion of the UKMHRA cGMP inspection with no critical or major observations is a strong validation of our robust quality systems. This further testifies our unwavering commitment to Good Manufacturing Practices and world class quality standards. The accolade not only reinforces the trust our global partners place in us, but strengthens our ability to serve patients worldwide.”
The facility, which manufactures solid and liquid dosage forms, is approved by the USFDA for solid dosages, creams and capsules; TGA-Australia for solid dosages, liquid orals, creams and ointments; and EU Malta, i.e., MMA - Malta Medicine Authority, for solid dosages. The plant also holds WHO-GMP approval and has successfully faced an audit by SAHPRA for solid dosages.
Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company’s turnover is US$ 175 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.
The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA.
Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 2,50,000 doctors belonging to various specialties.
Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc.
Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc.
On the international front, Indoco has tie-ups with large generic companies across the globe.
